H. Anne Pereira, Ph.D.

---

Summary

My laboratory investigates the role of a novel inflammatory mediator known as CAP37. We focus on the significance of this protein in host defense against severe infections including infections of the eye and in various inflammatory mediated diseases such as atherosclerosis and Alzheimer's disease. We currently employ a combination of cellular, immunological, biochemical and molecular approaches at the in vitro and in vivo level to solve these questions. Our long-term goals are to design new and effective antibiotics and anti-inflammatory therapeutics.

---

Research

This laboratory investigates the role of a novel inflammatory mediator known as CAP37. We focus on the significance of this protein in host defense against severe infections including infections of the eye and in various inflammatory mediated diseases such as atherosclerosis and Alzheimer's disease. We currently employ a combination of cellular, immunological, biochemical and molecular approaches at the in vitro and in vivo level to solve these questions. Our long-term goals are to design new and effective antibiotics and anti-inflammatory therapeutics.

Patents

---

Publications & Presentations

36. Pereira H A. CAP37, a neutrophil-derived multifunctional inflammatory mediator. Journal of leukocyte biology. 1995; 57 : 805-12

37. Pereira H A, Erdem I, Pohl J, Spitznagel J K. Synthetic bactericidal peptide based on CAP37: a 37-kDa human neutrophil granule-associated cationic antimicrobial protein chemotactic for monocytes. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90 : 4733-7

38. Morgan J G, Sukiennicki T, Pereira H A, Spitznagel J K, Guerra M E, Larrick J W. Cloning of the cDNA for the serine protease homolog CAP37/azurocidin, a microbicidal and chemotactic protein from human granulocytes. Journal of immunology (Baltimore, Md. : 1950). 1991; 147 : 3210-4

39. Morgan J G, Pereira H A, Sukiennicki T, Spitznagel J K, Larrick J W. Human neutrophil granule cationic protein CAP37 is a specific macrophage chemotaxin that shares homology with inflammatory proteinases. Advances in experimental medicine and biology. 1991; 305 : 89-96

40. Pohl J, Pereira H A, Martin N M, Spitznagel J K. Amino acid sequence of CAP37, a human neutrophil granule-derived antibacterial and monocyte-specific chemotactic glycoprotein structurally similar to neutrophil elastase. FEBS letters. 1990; 272 : 200-4

Grants

1. Oklahoma Shared Clinical and Translational Resources. NIH. Start Date: 2023. End Date: 2028.

2. Vision Science Training Program. NIH. Start Date: 2021. End Date: 2026.

3. STTR Phase 1: Multi-target Peptide Drug for Alzheimer's Disease. NIA. Start Date: 2024. End Date: 2025.

4. STTR Phase 1: Novel Ophthalmic Product for Corneal Infections and Injuries. NIH. Start Date: 2021. End Date: 2023.

5. Oklahoma Shared Clinical and Translational Resources. NIH. Start Date: 2018. End Date: 2023.

Awards and Honors

11. The Journal Record. On the Brink, Award for Innovation. Date: 2006.


12. Department of Pathology. Fred G Silva Research Award. Date: 1999.


13. American Heart Association. Established Investigator. Date: 1998.


14. OUHSC. Provosts' Research Award to Junior Faculty. Date: 1994.


15. OUHSC. Faculty Leadership Program. Date: 1992.

Education

1. Degree: Ph D. University of Melbourne. Date: 1982.


2. Degree: BSc (Honours) First class honours & First Place. University of Melbourne. Date: 1976.


3. Degree: BS. University of Melbourne. Date: 1975.

Administrative Assignments

1. Role: Dean. Scope: University. Description: Dean of the Graduate College. Responsible for Graduate Programs on the Health Sciences Campus and the Postdoctoral Office. Date: 2014.
Read More
2. Role: Associate Dean. Scope: College. Description: Responsible for Oversight of research activities in the College of Pharmacy, mentoring junior faculty and trainees. Date: 2009.
Read More